Alzheimer’s disease: zinc finger protein transcription factors (ZFP-TFs) dramatically reduce levels of tau


Researchers have used a genetic engineering strategy to dramatically reduce levels of tau – a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease – in an animal model of the condition.

The results, which come from investigators at Massachusetts General Hospital (MGH) and Sangamo Therapeutics Inc., could lead to a potentially promising treatment for patients with this devastating illness.

As described in Science Advances, the strategy involves a gene regulation technology called zinc finger protein transcription factors (ZFP-TFs), which are DNA-binding proteins that can be harnessed to target and affect the expression of specified genes.

In this case, the therapy was designed to target and silence the expression of the gene that codes for tau. Mice with Alzheimer’s disease received a single injection of the treatment – which employed a harmless virus to deliver the ZFP-TFs to cells – directly into the hippocampus region of the brain or intravenously into a blood vessel.

Treatment with ZFP-TFs reduced tau protein levels in the brain by 50% to 80% out to 11 months, the longest time point studied. Importantly, the therapy reversed some of the Alzheimer’s-related damage that was present in the animals’ brain cells.

“The technology worked just the way we had hoped—reducing tau substantially for as long as we looked, causing no side effects that we could see even over many, many months, and improving the pathological changes in the brains of the animals,” says senior author Bradley Hyman, MD, Ph.D., who directs the Alzheimer’s disease research unit at the MassGeneral Institute for Neurodegenerative Disease. “This suggests a plan forward to try to help patients.”

The simplicity of the therapy makes it an especially attractive approach. “This was the result of a single treatment of gene regulation therapy, which could be given by an injection into the bloodstream,” says Hyman. “While this therapy is far from patients—as much more development and safety testing would need to be done – it is a promising and exciting first step.”

During the years of the 2019–2020 outbreak of infection, one of the members of coronavirus, coronavirus disease-19 (COVID-19), becomes a global concern and is a public health emergency.[1,2] Infection by coronaviruses causes mild respiratory tract disorder, such as the common cold, but rare forms of infections with this family of viruses such as severe acute respiratory syndrome, Middle East respiratory syndrome coronavirus, and COVID-19 can be lethal and can remain long-term sequels.[2,3]

Unfortunately, there is no enough information on long-term sequels of infection by COVID-19 in an infected person.[3,4] However, based on some indirect evidence and documents, it can be hypostatized that infection with coronavirus family, especially COVID-19, can cause neurological disorder or exacerbate existing disease in an infected person, but it is not proven yet.[4,5] According to recent studies, angiotensin-converting enzyme 2 (ACE2) can be acts as functional and host receptor of COVID-19.[6,7]

It seems that some parts of the sequels of COVID-19 in the respiratory and cardiovascular system were mediated via the inhibition of ACE-2, but the mechanism of involvement of this ACE-2 was not exactly clarified.[8,9] On the other way, it was suggested that ACE-2 is one of the main enzymes which by the mediation of some important proteins such as Mas protein regulates normal brain functions such as cognitive activity and release of neurotrophic factors such as brain-derived neurotrophic factor (BDNF).[10,11]

Furthermore, there are novel studies that indicate that the reduced activity of the ACE-2/Ang (1–7)/Mas axis is strongly linked to Tau hyper-phosphorylation (inactivation) and aggregation of neural internal microtubules and amyloid-β (Aβ) peptides.[12,13] According to these data, it was established that the reduction of ACE-2 activity or expression can disturb normal brain cognition activity or can exacerbate Alzheimer’s disease.[13,14]

Thus, according to the mentioned studies, it was hypothesized that infection with COVID-19 can target and reduce ACE-2 activity, and/or expression, and probably its downstream Mas/BDNF axis, in the brain cells, and according to these data, it can be expected that infection by COVID-19 may cause disturbances in cognition activity and also exacerbate cognitive impairment in infected person with Alzheimer’s disease [Figure 1].

An external file that holds a picture, illustration, etc.
Object name is ABR-9-36-g001.jpg
Figure 1
In the pathophysiology of Alzheimer’s disease, some intrinsic and extrinsic triggers cause activation of some kinases which led to hyper-phosphorylation of Tau protein. This Tau hyper-phosphorylation causes disability of microtubules, which consequently causes aggregation of tau protein (Tau fibril) and neuro-filaments. On the other way, some intrinsic and extrinsic triggers cause activation of secretase family enzymes which initiate degradation of Amyloid precursor protein and led to production and formation of amyloid-beta. Amyloid-beta, Tau fibril/neuro-filament causes degeneration neural cells which cause Alzheimer’s disease or dementia. As mentioned in the text, angiotensin-converting enzyme-2 causes inhibition of secretases family enzymes and kinases enzymes which can inhibit occurrences of Alzheimer’s disease, dementia, or cognition impairment. According to some indirect evidence, it seems that infection with the COVID-19 virus can cause inhibition of the angiotensin-converting enzyme-2 signaling pathway, and it might be can have long-term neurological sequels such as activation of Alzheimer’s or dementia triggers signaling pathway

reference link :

reference link :


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.